# Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density

> **NCT00043186** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 412 (actual)

## Conditions studied

- Low Bone Mineral Density

## Interventions

- **DRUG:** Placebo
- **DRUG:** Denosumab
- **DRUG:** Alendronate

## Key facts

- **NCT ID:** NCT00043186
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2007-04
- **Final completion:** 2007-06
- **Target enrollment:** 412 (ACTUAL)
- **Last updated:** 2013-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00043186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00043186, "Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00043186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*